Our research aimed to design and perform computational analysis of the fusion proteins with high affinity and specificity for human serum albumin and a protease-resistant GLP-1 peptide to produce potent GLP-1 agonists with an extended plasma half-life for the treatment of type 2 diabetes. Here, ALB is linked to type 2 diabetes mellitus.